Vincent C Emery

List of Publications by Year in descending order

Source: https://exaly.com/author-pdf/427853/publications.pdf Version: 2024-02-01



#	Article	IF	CITATIONS
1	The "Silent―Global Burden of Congenital Cytomegalovirus. Clinical Microbiology Reviews, 2013, 26, 86-102.	13.6	771
2	Digital technologies in the public-health response to COVID-19. Nature Medicine, 2020, 26, 1183-1192.	30.7	695
3	Genetic content of wild-type human cytomegalovirus. Journal of General Virology, 2004, 85, 1301-1312.	2.9	500
4	Application of viral-load kinetics to identify patients who develop cytomegalovirus disease after transplantation. Lancet, The, 2000, 355, 2032-2036.	13.7	496
5	Cytomegalovirus glycoprotein-B vaccine with MF59 adjuvant in transplant recipients: a phase 2 randomised placebo-controlled trial. Lancet, The, 2011, 377, 1256-1263.	13.7	352
6	Cytomegalovirus in transplantation ? challenging the status quo. Clinical Transplantation, 2007, 21, 149-158.	1.6	245
7	The Dynamics of Human Cytomegalovirus Replication in Vivo. Journal of Experimental Medicine, 1999, 190, 177-182.	8.5	244
8	Diagnosis of postâ€ŧransplant lymphoproliferative disorder in solid organ transplant recipients – BCSH and BTS Guidelines. British Journal of Haematology, 2010, 149, 675-692.	2.5	211
9	Importance of cytomegalovirus viraemia in risk of disease progression and death in HIV-infected patients receiving highly active antiretroviral therapy. Lancet, The, 2004, 363, 2116-2121.	13.7	201
10	Management of postâ€ŧransplant lymphoproliferative disorder in adult solid organ transplant recipients – BCSH and BTS Guidelines. British Journal of Haematology, 2010, 149, 693-705.	2.5	191
11	Kinetics of Acute Hepatitis B Virus Infection in Humans. Journal of Experimental Medicine, 2001, 193, 847-854.	8.5	178
12	Sequential mutations associated with adaptation of human cytomegalovirus to growth in cell culture. Journal of General Virology, 2010, 91, 1535-1546.	2.9	164
13	Cytomegalovirus Replication Kinetics in Solid Organ Transplant Recipients Managed by Preemptive Therapy. American Journal of Transplantation, 2012, 12, 2457-2464.	4.7	154
14	Cytomegalovirus (CMV) viraemia detected by polymerase chain reaction identifies a group of HIV-positive patients at high risk of CMV disease. Aids, 1997, 11, 889-893.	2.2	146
15	Human herpesviruses 6 and 7 as potential pathogens after liver transplant: Prospective comparison with the effect of cytomegalovirus. Journal of Medical Virology, 1999, 59, 496-501.	5.0	146
16	Review of Cytomegalovirus Infection Findings With Mammalian Target of Rapamycin Inhibitor-Based Immunosuppressive Therapy in De Novo Renal Transplant Recipients. Transplantation, 2012, 93, 1075-1085.	1.0	129
17	Two novel spliced genes in human cytomegalovirus. Journal of General Virology, 2003, 84, 1117-1122.	2.9	126
18	PROSPECTIVE STUDY OF HUMAN BETAHERPESVIRUSES AFTER RENAL TRANSPLANTATION. Transplantation, 2000, 69, 2400-2404.	1.0	126

#	Article	IF	CITATIONS
19	Human Cytomegalovirus (HCMV) Replication Dynamics in HCMVâ€Naive and â€Experienced Immunocompromised Hosts. Journal of Infectious Diseases, 2002, 185, 1723-1728.	4.0	112
20	Cytomegalovirus retinitis in AIDS patients: influence of cytomegaloviral load on response to ganciclovir, time to recurrence and survival. Aids, 1996, 10, 1515-1520.	2.2	111
21	PROVISION OF PROGNOSTIC INFORMATION IN IMMUNOCOMPROMISED PATIENTS BY ROUTINE APPLICATION OF THE POLYMERASE CHAIN REACTION FOR CYTOMEGALOVIRUS. Transplantation, 1993, 56, 867-871.	1.0	106
22	Human Cytomegalovirus Seropositivity Is Associated With Impaired Vascular Function. Circulation, 2003, 108, 678-683.	1.6	105
23	Changes in the natural history of cytomegalovirus retinitis following the introduction of highly active antiretroviral therapy. Aids, 2000, 14, 1163-1170.	2.2	98
24	Impact of Genetic Polymorphisms in Cytomegalovirus Glycoprotein B on Outcomes in Solidâ€Organ Transplant Recipients with Cytomegalovirus Disease. Clinical Infectious Diseases, 2009, 49, 1160-1166.	5.8	96
25	Replicative fitness in vivo of HIV-1 variants with multiple drug resistance-associated mutations. Journal of Medical Virology, 2001, 65, 218-224.	5.0	94
26	Loss of cytomegalovirus (CMV) viraemia following highly active antiretroviral therapy in the absence of specific anti-CMV therapy. Aids, 1999, 13, 1203-1206.	2.2	93
27	Management of cytomegalovirus infection in haemopoietic stem cell transplantation. British Journal of Haematology, 2013, 162, 25-39.	2.5	92
28	A Randomized, Controlled Trial Comparing Ganciclovir to Ganciclovir Plus Foscarnet (Each at Half) Tj ETQq0 0 0 r Infectious Diseases, 2004, 189, 1355-1361.	gBT /Overl 4.0	lock 10 Tf 50 87
29	Prophylaxis for CMV shouldnot now replace pre-emptive therapy in solid organ transplantation. Reviews in Medical Virology, 2001, 11, 83-86.	8.3	84
30	Acute cytomegalovirus infection in Kenyan HIV-infected infants. Aids, 2009, 23, 2173-2181.	2.2	80
31	Homology between the human cytomegalovirus RL11 gene family and human adenovirus E3 genes. Journal of General Virology, 2003, 84, 657-663.	2.9	79
32	The development of multiple expression vectors for high level synthesis of eukaryotic proteins: expression of LCMV-N and AcNPV polyhedrin protein by a recombinant baculovirus. Protein Engineering, Design and Selection, 1987, 1, 359-366.	2.1	75
33	The use of baculoviruses as expression vectors. Applied Biochemistry and Biotechnology, 1993, 42, 137-159.	2.9	72
34	Distinct HIV-1 long terminal repeat quasispecies present in nervous tissues compared to that in lung, blood and lymphoid tissues of an AIDS patient. Aids, 1995, 9, 675-684.	2.2	72
35	The ESCRT machinery is not required for human cytomegalovirus envelopment. Cellular Microbiology, 2007, 9, 2955-2967.	2.1	65
36	Summary of the British Transplantation Society Guidelines for the Prevention and Management of CMV Disease After Solid Organ Transplantation. Transplantation, 2011, 92, 1181-1187.	1.0	64

#	Article	IF	CITATIONS
37	Quantity of human cytomegalovirus (CMV) DNAemia as a risk factor for CMV disease in renal allograft recipients: Relationship with donor/recipient CMV serostatus, receipt of augmented methylprednisolone and antithymocyte globulin (ATG). , 1999, 58, 182-187.		60
38	Effect of maintenance immunosuppressive drugs on virus pathobiology: evidence and potential mechanisms. Reviews in Medical Virology, 2013, 23, 97-125.	8.3	60
39	The U69 Gene of Human Herpesvirus 6 Encodes a Protein Kinase Which Can Confer Ganciclovir Sensitivity to Baculoviruses. Journal of Virology, 1999, 73, 3284-3291.	3.4	60
40	Detection of human retrovirus 5 in patients with arthritis and systemic lupus erythematosus. Arthritis and Rheumatism, 1999, 42, 448-454.	6.7	58
41	Incidence and Dynamics of Epstein-Barr Virus Reactivation After Alemtuzumab-Based Conditioning for Allogeneic Hematopoietic Stem-Cell Transplantation. Transplantation, 2010, 90, 564-570.	1.0	57
42	Cytomegalovirus (CMV) Resistance to Antivirals. American Journal of Transplantation, 2001, 1, 307-312.	4.7	57
43	Cytomegalovirus polymerase chain reaction viraemia in patients receiving ganciclovir maintenance therapy for retinitis. Aids, 1998, 12, 605-611.	2.2	54
44	Genotypic analysis of two hypervariable human cytomegalovirus genes. Journal of Medical Virology, 2008, 80, 1615-1623.	5.0	54
45	Porcine cytomegalovirus in pigs being bred for xenograft organs: progress towards control. Xenotransplantation, 2003, 10, 142-148.	2.8	52
46	Interactions between ?-herpesviruses and human immunodeficiency virus in vivo: Evidence for increased human immunodeficiency viral load in the presence of human herpesvirus 6. , 1999, 57, 278-282.		47
47	Focus on New Drugs in Development Against Human Cytomegalovirus. Drugs, 2002, 62, 1853-1858.	10.9	46
48	A multiplex PCR assay for the simultaneous detection of human herpesvirus 6 and human herpesvirus 7, with typing of HHV-6 by enzyme cleavage of PCR products. Journal of Virological Methods, 1998, 70, 29-36.	2.1	45
49	Predicted α-helix/β-sheet secondary structures for the zinc-binding motifs of human papillomavirus E7 and E6 proteins by consensus prediction averaging and spectroscopic studies of E7. Biochemical Journal, 1996, 319, 229-239.	3.7	44
50	Quantitation of Porcine Cytomegalovirus in Pig Tissues by PCR. Journal of Clinical Microbiology, 2001, 39, 1155-1156.	3.9	44
51	Compartmentalized Cytomegalovirus Replication and Transmission in the Setting of Maternal HIV-1 Infection. Clinical Infectious Diseases, 2014, 58, 564-572.	5.8	44
52	Towards an ultra-rapid smartphone- connected test for infectious diseases. Scientific Reports, 2017, 7, 11971.	3.3	42
53	Sequence variability of the αâ€chemokine UL146 from clinical strains of human cytomegalovirus. Journal of Medical Virology, 2004, 74, 573-579.	5.0	41
54	The detection of cytomegalovirus DNA in maternal plasma is associated with mortality in HIV-1-infected women and their infants. Aids, 2009, 23, 117-124.	2.2	40

#	Article	IF	CITATIONS
55	Maternal Valacyclovir and Infant Cytomegalovirus Acquisition: A Randomized Controlled Trial among HIV-Infected Women. PLoS ONE, 2014, 9, e87855.	2.5	40
56	Eliminating PCR contamination: is UV irradiation the answer?. Journal of Virological Methods, 1991, 33, 375-382.	2.1	38
57	Quantity of cytomegalovirus DNA in different leukocyte populations during active infection in vivo and the presence of gB and UL18 transcripts. Journal of Medical Virology, 2001, 64, 283-289.	5.0	38
58	Enhancement of humoral immune responses to a human cytomegalovirus DNA vaccine: Adjuvant effects of aluminum phosphate and CpG oligodeoxynucleotides. Journal of Medical Virology, 2003, 70, 86-90.	5.0	38
59	Randomized Controlled Trials to Define Viral Load Thresholds for Cytomegalovirus Pre-Emptive Therapy. PLoS ONE, 2016, 11, e0163722.	2.5	36
60	Development of a quantitative competitive polymerase chain reaction for human herpesvirus 8. Journal of Virological Methods, 1997, 64, 19-26.	2.1	34
61	Human Herpesviruses 6 and 7 in Solid Organ Transplant Recipients. Clinical Infectious Diseases, 2001, 32, 1357-1360.	5.8	34
62	Management of CMV infection and disease in transplant patients. 27-29 February 2004. Herpes: the Journal of the IHMF, 2004, 11, 77-86.	0.3	34
63	Cytomegalovirus, human herpesvirus-6, and human herpesvirus-7 in hematological patients. Seminars in Hematology, 2003, 40, 154-162.	3.4	33
64	Markers of HIV-1 disease progression in individuals with haemophilia coinfected with hepatitis C virus: a longitudinal study. Lancet, The, 2002, 360, 1546-1551.	13.7	30
65	Influence of cytomegalovirus infection on immune cell phenotypes in patients with common variable immunodeficiency. Journal of Allergy and Clinical Immunology, 2012, 129, 1349-1356.e3.	2.9	30
66	Glucocorticosteroids trigger reactivation of human cytomegalovirus from latently infected myeloid cells and increase the risk for HCMV infection in D+R+ liver transplant patients. Journal of General Virology, 2015, 96, 131-143.	2.9	30
67	Inflammation in common variable immunodeficiency is associated with a distinct CD8+ response to cytomegalovirus. Journal of Allergy and Clinical Immunology, 2011, 127, 1385-1393.e4.	2.9	29
68	Viral Dynamics during Active Cytomegalovirus Infection and Pathology. Intervirology, 1999, 42, 405-411.	2.8	28
69	Rapid reconstitution of humoral immunity against cytomegalovirus but not HIV following highly active antiretroviral therapy. Aids, 2002, 16, 2129-2135.	2.2	28
70	Acute Cytomegalovirus Infection Is Associated with Increased Frequencies of Activated and Apoptosis-Vulnerable T Cells in HIV-1-Infected Infants. Journal of Virology, 2012, 86, 11373-11379.	3.4	28
71	Taming the Transplantation Troll by Targeting Terminase. New England Journal of Medicine, 2014, 370, 1844-1846.	27.0	28
72	Cytomegalovirus in pregnancy and the neonate. F1000Research, 2017, 6, 138.	1.6	28

#	Article	IF	CITATIONS
73	Exploring the bidirectional interactions between human cytomegalovirus and hepatitis C virus replication after liver transplantation. Liver Transplantation, 2007, 13, 130-135.	2.4	27
74	Cytomegalovirus quantification: Where to next in optimising patient management?. Journal of Clinical Virology, 2011, 51, 223-228.	3.1	27
75	Vertical Cytomegalovirus Transmission From HIV-Infected Women Randomized to Formula-Feed or Breastfeed Their Infants. Journal of Infectious Diseases, 2016, 213, 992-998.	4.0	25
76	Cytomegalovirus, human herpesvirus-6, and human herpesvirus-7 in hematological patients. Seminars in Hematology, 2003, 40, 154-162.	3.4	25
77	Development of a point mutation assay for the detection of human cytomegalovirus UL97 mutations associated with ganciclovir resistance. Journal of Virological Methods, 1997, 68, 225-234.	2.1	24
78	Azidodeoxythymidine and didehydrodeoxythymidine as inhibitors and substrates of the human herpesvirus 8 thymidine kinase. Journal of Antimicrobial Chemotherapy, 2002, 49, 359-366.	3.0	24
79	Human cytomegalovirus (HCMV) replication kinetics in stem cell transplant recipients following anti-HCMV therapy. Journal of Clinical Virology, 2010, 49, 32-36.	3.1	24
80	Susceptibility of porcine cytomegalovirus to antiviral drugs. Journal of Antimicrobial Chemotherapy, 2004, 53, 975-980.	3.0	23
81	Evolution of hepatitis B virus during primary infection in humans: Transient generation of cytotoxic T-cell mutants. Gastroenterology, 2004, 127, 1131-1138.	1.3	23
82	Detection of cytomegalovirus in human placental cells by polymerase chain reaction. Apmis, 2006, 114, 764-771.	2.0	22
83	Importance of the cytomegalovirus seropositive recipient as a contributor to disease burden after solid organ transplantation. Journal of Clinical Virology, 2012, 54, 125-129.	3.1	21
84	Cytomegalovirus and the Aging Population. Drugs and Aging, 2001, 18, 927-933.	2.7	20
85	The effects of maribavir on the autophosphorylation of ganciclovir resistant mutants of the cytomegalovirus UL97 protein. Herpesviridae, 2010, 1, 4.	2.7	18
86	Cytomegalovirus: recent progress in understanding pathogenesis and control. QJM - Monthly Journal of the Association of Physicians, 2012, 105, 401-405.	0.5	17
87	Hypothetical structure of the membrane-associated E5 oncoprotein of human papillomavirus type 16. Biochemical Society Transactions, 1994, 22, 439S-439S.	3.4	15
88	β-Sheet secondary structure of an LDL receptor domain from complement factor I by consensus structure predictions and spectroscopy. FEBS Letters, 1995, 371, 199-203.	2.8	15
89	A non-radioisotopic quantitative competitive polymerase chain reaction method: application in measurement of human herpesvirus 7 load. Journal of Virological Methods, 2000, 87, 177-181.	2.1	14
90	Modelling cytomegalovirus replication patterns in the human host: factors important for pathogenesis. Proceedings of the Royal Society B: Biological Sciences, 2006, 273, 1961-1967.	2.6	14

#	Article	IF	CITATIONS
91	Differential Effects of Prednisolone and Azathioprine on the Development of Human Cytomegalovirus Replication Post Liver Transplantation. Transplantation, 2007, 84, 605-610.	1.0	14
92	Sequence microheterogeneity in the long control region of clinical isolates of human papillomavirus type 16. Journal of Medical Virology, 1993, 39, 267-272.	5.0	13
93	HHV-6A, 6B, and 7: persistence in the population: epidemiology and transmission. , 0, , 875-882.		12
94	Differential decay kinetics of human cytomegalovirus glycoprotein B genotypes following antiviral chemotherapy. Journal of Clinical Virology, 2012, 54, 56-60.	3.1	12
95	Novel decay dynamics revealed for virus-mediated drug activation in cytomegalovirus infection. PLoS Pathogens, 2017, 13, e1006299.	4.7	12
96	Sequence variation within the human immunodeficiency virus V3 loop at seroconversion. Journal of Medical Virology, 1993, 41, 270-274.	5.0	11
97	The Prognostic Value of a Single Hepatitis C Virus RNA Load Measurement Taken Early after Human Immunodeficiency Virus Seroconversion. Journal of Infectious Diseases, 2002, 186, 470-476.	4.0	11
98	Patients with B cell chronic lymphocytic leukaemia have an expanded population of CD4 ⁺ perforin expressing T cells enriched for human cytomegalovirus specificity and an effectorâ€memory phenotype. British Journal of Haematology, 2010, 148, 274-284.	2.5	11
99	Facing the Facts: The Indirect Effects of Cytomegalovirus. Transplantation, 2007, 84, S7-S10.	1.0	10
100	Extensive human cytomegalovirus (HCMV) genomic DNA in the renal tubular epithelium early after renal transplantation: Relationship with HCMV DNAemia and longâ€ŧerm graft function. Journal of Medical Virology, 2010, 82, 85-93.	5.0	10
101	Compartmentalized dynamics of cytomegalovirus replication in treated congenital infection. Journal of Clinical Virology, 2016, 82, 152-158.	3.1	10
102	Restimulating Interest in Cytomegalovirus as a Cofactor for HIV Infection. Journal of Infectious Diseases, 2015, 211, 169-171.	4.0	8
103	Maternal Highly Active Antiretroviral Therapy Reduces Vertical Cytomegalovirus Transmission But Does Not Reduce Breast Milk Cytomegalovirus Levels. AIDS Research and Human Retroviruses, 2017, 33, 332-338.	1.1	8
104	Sequence flexibility of the immunodominant HLA A*0201 restricted ppUL83 CD8 T ell epitope of human cytomegalovirus. Journal of Medical Virology, 2010, 82, 94-103.	5.0	7
105	<scp>CMV</scp> infected or not <scp>CMV</scp> infected: That is the question. European Journal of Immunology, 2013, 43, 886-888.	2.9	7
106	Quantitative differences in the distribution of zidovudine resistance mutations in multiple post-mortem tissues from AIDS patients. , 1998, 55, 138-146.		6
107	The effect of highly active antiretroviral therapy for HIV on the anti-HCV specific humoral immune response. Journal of Medical Virology, 2004, 72, 187-193.	5.0	6
108	Immunotherapy and Vaccination After Transplant: The Present, the Future. Infectious Disease Clinics of North America, 2010, 24, 515-529.	5.1	4

#	Article	IF	CITATIONS
109	Could a vaccine against immune-evading cytomegalovirus become a reality?. Expert Review of Vaccines, 2011, 10, 1109-1111.	4.4	3
110	Detection of human cytomegalovirus polymerase chain reaction products using oligonucleotide probes directly conjugated to alkaline phosphatase. Journal of Virological Methods, 1996, 61, 145-150.	2.1	2
111	TUNING TO THE RIGHT FREQUENCY: CYTOTOXIC T LYMPHOCYTES AND CYTOMEGALOVIRUS. Transplantation, 2000, 69, 2241-2242.	1.0	2
112	A T-cell protein which recognizes a palindromic DNA sequence in the negative regulatory element of the HIV-1 long terminal repeat with homology to steroid/thyroid hormone receptor binding sites. Biochemical Society Transactions, 1990, 18, 555-556.	3.4	1
113	Newer human herpesviruses in transplantation. Current Opinion in Organ Transplantation, 2000, 5, 203-209.	1.6	1
114	Clinical xenotransplantation. Lancet, The, 2003, 362, 1421.	13.7	1
115	Immunotherapy and Vaccination After Transplant: The Present, the Future. Hematology/Oncology Clinics of North America, 2011, 25, 215-229.	2.2	1
116	Vaccination against cytomegalovirus: Still at base camp?. American Journal of Transplantation, 2018, 18, 2847-2848.	4.7	1
117	Production of Plaques in Monolayer Tissue Cultures by Single Particles of an Animal Virus. , 1996, 6, 61-64.		0
118	A Longitudinal Study of Human Papillomavirus 16 Positivity in the Development of Lower Genital Intraepithelial Neoplasia in Immunosuppressed Women. Journal of Lower Genital Tract Disease, 1999, 3, 163-170.	1.9	0
119	Cd8 Cytotoxic Lymphocyte Responses against Cytomegalovirus in Renal Transplant Patients and Healthy Individuals. Clinical Science, 2002, 103, 28P-29P.	0.0	0
120	Molecular diagnosis of cytomegalovirus disease. , 2002, , 467-473.		0
121	Multidrug Resistance in Human Cytomegalovirus. , 2004, , 379-391.		0
122	Respiratory Virus and Mycoplasmal Infections in the Immunocompromised. , 1996, , 359-381.		0
123	Baculovirus Vectors. Springer Protocols, 1998, , 219-233.	0.3	0